https://www.selleckchem.com/pr....oducts/derazantinib.
20 (0.83-1.74), 1.27 (1.07-1.5, 1.12 (0.95-1.31), 0.98 (0.85-1.14), and 1.03 (0.87-1.22) respectively. AGI use was associated with higher risks of all-cause mortality and non-cardiovascular death in insulin-treated patients with T2DM. Therefore, adding AGIs in insulin-treated patients may not be appropriate. AGI use was associated with higher risks of all-cause mortality and non-cardiovascular death in insulin-treated patients with T2DM. Therefore, adding AGIs in insulin-treated patients may not be appropriate. Providers face inc
Like
Comment
Share
